Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Holzer, Timothy R ^a   Fulford, Angie D ^a   Nedderman, Drew M ^a   Umberger, Tara S ^a   Hozak, Rebecca R ^a   Joshi, Adarsh ^a   Melemed, Symantha A ^a   Benjamin, Laura E ^a   Plowman, Gregory D ^a   Schade, Andrew E ^a   Ackermann, Bradley L ^a   Konrad, Robert J ^a   Nasir, Aejaz ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN RECEPTOR 2;

AGED; FEMALE; HUMAN; IN VITRO STUDY; KAPLAN MEIER METHOD; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FEMALE; HUMANS; IN VITRO TECHNIQUES; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84893528074     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080292     Document Type: Article

References (68)

1. Ferrara N, Gerber HP and LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676. (Pubitemid 36749215)
2. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, et al. (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56: 549-580. (Pubitemid 39658463)
3. Yang XH, Man XY, Cai SQ, Yao YG, Bu ZY, et al. (2006) Expression of VEGFR-2 on HaCaT cells is regulated by VEGF and plays an active role in mediating VEGF induced effects. Biochem Biophys Res Commun 349: 31-38.
4. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, et al. (1999) Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59: 5209-5218. (Pubitemid 29503984)
5. Zhu Z, Bohlen P and Witte L (2002) Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr Cancer Drug Targets 2: 135-156. (Pubitemid 34625481)
6. Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, et al. (2000) Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 89: 488-499. (Pubitemid 30640095)
7. Inoue K, Slaton JW, Davis DW, Hicklin DJ, McConkey DJ, et al. (2000) Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res 6: 2635-2643. (Pubitemid 30482098)
8. Camidge DR, Ballas MS, Dubey S, Haigentz M, Rosen PJ, et al. (2010) A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC). 2010 American Society of Clinical Oncology Annual Meeting: abstract 7588.
9. Carvajal RD, Wong MK, Thompson JA, Gordon MS, Lewis KD, et al. (2010) A phase II randomized study of ramucirumab (IMC-1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM). 2010 American Society of Clinical Oncology Annual Meeting: abstract 8519.
10. Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, et al. (2010) A phase 2 study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC): Updated results (CP12-0710/NCT00627042). 2010 International Liver Cancer Association (ILCA) Conference: abstract O-033.
11. Garcia JA, Hudes GR, Choueiri TK, Stadler WM, Wood LS, et al. (2010) Phase II study of IMC-1121B in patients with metastatic renal cancer (mRCC) following VEGFR-2 tyrosine kinase inhibitor (TKI) therapy (IMCL CP12-0605/NCT00515697). 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium: abstract 326.
12. Garcia-Carbonero R, Rivera F, Maurel J, Ayoub J-PM, Moore MJ, et al. (2012) A phase II, open-label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): CP12-0709/NCT00862784. 2012 American Society of Clinical Oncology Gastrointestinal Cancers Symposium abstract 533.
13. Penson RT, Moore KN, Fleming GF, Braly PS, Schimp VL, et al. (2012) A phase II, open-label, multicenter study of IMC-1121B (ramucirumab; RAM) monotherapy in the treatment of persistent or recurrent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal (PPC) carcinoma (CP12-0711/NCT00721162). ASCO Meeting Abstracts: abstract 5012.
14. Amaya H, Tanigawa N, Lu C, Matsumura M, Shimomatsuya T, et al. (1997) Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett 119: 227-235. (Pubitemid 27478108)
15. Duff SE, Jeziorska M, Rosa DD, Kumar S, Haboubi N, et al. (2006) Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. Eur J Cancer 42: 112-117. (Pubitemid 41814541)
16. Price DJ, Miralem T, Jiang S, Steinberg R and Avraham H (2001) Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 12: 129-135. (Pubitemid 32677998)
17. Ryden L, Linderholm B, Nielsen NH, Emdin S, Jonsson PE, et al. (2003) Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat 82: 147-154. (Pubitemid 37521970)
18. Wulfing P, Kersting C, Buerger H, Mattsson B, Mesters R, et al. (2005) Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br J Cancer 92: 1720-1728. (Pubitemid 40756484)
19. Ghosh S, Sullivan CA, Zerkowski MP, Molinaro AM, Rimm DL, et al. (2008) High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol 39: 1835-1843.
20. Koukourakis MI, Giatromanolaki A, Thorpe PE, Brekken RA, Sivridis E, et al. (2000) Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 60: 3088-3095. (Pubitemid 30395839)
21. Kajita T, Ohta Y, Kimura K, Tamura M, Tanaka Y, et al. (2001) The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer 85: 255-260. (Pubitemid 32695748)
22. Donnem T, Al-Saad S, Al-Shibli K, Delghandi MP, Persson M, et al. (2007) Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res 13: 6649-6657. (Pubitemid 350206800)
23. Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, et al. (1995) Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87: 506-516.
24. Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, et al. (1999) Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54: 567-572. (Pubitemid 29407042)
25. Itakura J, Ishiwata T, Shen B, Kornmann M and Korc M (2000) Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 85: 27-34.
26. Konig J, Tolnay E, Wiethege T and Muller K (2000) Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma. Respiration 67: 36-40. (Pubitemid 30114163)
27. Lacal PM, Failla CM, Pagani E, Odorisio T, Schietroma C, et al. (2000) Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 115: 1000-1007. (Pubitemid 32037443)
28. Kollermann J and Helpap B (2001) Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. Am J Clin Pathol 116: 115-121. (Pubitemid 32601135)
29. Smith NR, Baker D, James NH, Ratcliffe K, Jenkins M, et al. (2010) Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 16: 3548-3561.
30. Anagnostou VK, Bepler G, Syrigos KN, Tanoue L, Gettinger S, et al. (2009) High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma. Clin Cancer Res 15: 4157-4164.
31. Anagnostou VK, Syrigos KN, Bepler G, Homer RJ and Rimm DL (2009) Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol 27: 271-278.
32. Hanna JA, Wimberly H, Kumar S, Slack F, Agarwal S, et al. (2012) Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization. Biotechniques 52: 235-245.
33. Zito CR, Jilaveanu LB, Anagnostou V, Rimm D, Bepler G, et al. (2012) Multilevel targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS ONE 7: e31331.
34. Camp RL, Chung GG and Rimm DL (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8: 1323-1327. (Pubitemid 35373567)
35. Rekhtman N, Ang DC, Sima CS, Travis WD and Moreira AL (2011) Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 24: 1348-1359.
36. Cox D (1972) Regression models and life tables. J R Stat Soc Ser B 20: 187-220.
37. Miller R and Siegmund D (1982) Maximally selected Chi square statistics. Biometrics 48: 1011-1016. (Pubitemid 14272808)
38. Shibuya K, Komaki R, Shintani T, Itasaka S, Ryan A, et al. (2007) Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 69: 1534-1543. (Pubitemid 350116420)
39. Wu W, Onn A, Isobe T, Itasaka S, Langley RR, et al. (2007) Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 6: 471-483. (Pubitemid 46332449)
40. Bordeaux J, Welsh A, Agarwal S, Killiam E, Baquero M, et al. (2010) Antibody validation. Biotechniques 48: 197-209.
41. Santos SC, Miguel C, Domingues I, Calado A, Zhu Z, et al. (2007) VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing. Exp Cell Res 313: 1561-1574. (Pubitemid 46589434)
42. Giatromanolaki A, Koukourakis MI, Sivridis E, Chlouverakis G, Vourvouhaki E, et al. (2007) Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur J Clin Invest 37: 878-886. (Pubitemid 350029203)
43. Domingues I, Rino J, Demmers JA, de Lanerolle P and Santos SC (2011) VEGFR2 Translocates to the Nucleus to Regulate Its Own Transcription. PLoS ONE 6: e25668.
44. Sher I, Adham SA, Petrik J and Coomber BL (2009) Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. Int J Cancer 124: 553-561.
45. Stewart M, Turley H, Cook N, Pezzella F, Pillai G, et al. (2003) The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study. Histopathology 43: 33-39. (Pubitemid 36836585)
46. Gerber HP and Ferrara N (2003) The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med (Berl) 81: 20-31.
47. Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, et al. (2002) VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417: 954-958. (Pubitemid 34716872)
48. Santos SC and Dias S (2004) Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 103: 3883-3889. (Pubitemid 38596309)
49. Lu C and Kerbel RS (1993) Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 120: 1281-1288. (Pubitemid 23064182)
50. Miettinen M, Rikala MS, Rys J, Lasota J and Wang ZF (2012) Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors. Am J Surg Pathol 36: 629-639.
51. Carrillo de Santa Pau E, Arias FC, Caso Pelaez E, Munoz Molina GM, Sanchez Hernandez I, et al. (2009) Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer 115: 1701-1712.
52. Pajares MJ, Agorreta J, Larrayoz M, Vesin A, Ezponda T, et al. (2012) Expression of Tumor-Derived Vascular Endothelial Growth Factor and Its Receptors Is Associated With Outcome in Early Squamous Cell Carcinoma of the Lung. J Clin Oncol.
53. Molhoek KR, Erdag G, Rasamny JK, Murphy C, Deacon D, et al. (2011) VEGFR-2 expression in human melanoma: revised assessment. Int J Cancer 129: 2807-2815.
54. Ferrara N and Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438: 967-974. (Pubitemid 43093963)
55. Kerbel RS and Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4: 423-436. (Pubitemid 38745528)
56. Gasparini G, Longo R, Fanelli M and Teicher BA (2005) Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 23: 1295-1311. (Pubitemid 46202288)
57. Douillard JY, Laporte S, Fossella F, Georgoulias V, Pujol JL, et al. (2007) Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol 2: 939-946. (Pubitemid 47511598)
58. Grossi F, Aita M, Defferrari C, Rosetti F, Brianti A, et al. (2009) Impact of thir-dgeneration drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 14: 497-510.
59. Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, et al. (2005) Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47: 69-80. (Pubitemid 39643243)
60. Grossi F, Kubota K, Cappuzzo F, de Marinis F, Gridelli C, et al. (2010) Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. Oncologist 15: 1102-1112.
61. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, et al. (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clinical cancer research: an official journal of the American Association for Cancer Research 2: 1843-1849.
62. Adham SA, Sher I and Coomber BL (2010) Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells. Lab Invest 90: 709-723.
63. Soker S, Miao HQ, Nomi M, Takashima S and Klagsbrun M (2002) VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem 85: 357-368. (Pubitemid 34274903)
64. Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, et al. (2006) Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer 106: 1677-1684.
65. Yao J, Wu X, Zhuang G, Kasman IM, Vogt T, et al. (2011) Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci U S A 108: 11590-11595.
66. Miao HQ, Lee P, Lin H, Soker S and Klagsbrun M (2000) Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J 14: 2532-2539.
67. Otrock ZK, Makarem JA and Shamseddine AI (2007) Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis 38: 258-268. (Pubitemid 46518176)
68. Decaussin M, Sartelet H, Robert C, Moro D, Claraz C, et al. (1999) Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 188: 369-377. (Pubitemid 29327434)